JOHNSON & JOHNSON

For the period ended Dec 28, 2025. Filed Feb 11, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 11, 2026

JNJ$280.78-0.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated statements of comprehensive income

Johnson & Johnson and subsidiaries consolidated statements of comprehensive income

	2025	2024	2023
Net earnings	$26,804	14,066	35,153
Other comprehensive income (loss), net of tax
Foreign currency translation	(5,506)	1,708	(3,221)
Securities:
Unrealized holding gain (loss) arising during period	(1)	2	26
Reclassifications to earnings	—	—	—
Net change	(1)	2	26
Employee benefit plans:
Prior service credit (cost), net of amortization	(144)	(154)	(149)
Gain (loss), net of amortization	1,130	541	(1,183)
Consumer settlement/ curtailment	—	—	23
Effect of exchange rates	(128)	62	(90)
Net change	858	449	(1,399)
Derivatives & hedges:
Unrealized gain (loss) arising during period	1,953	(511)	422
Reclassifications to earnings	(493)	(862)	(569)
Net change	1,460	(1,373)	(147)
Other comprehensive income (loss)	(3,189)	786	(4,741)
Comprehensive income	$23,615	14,852	30,412

The tax cost/(benefit) effects in other comprehensive income for the fiscal years 2025, 2024 and 2023 respectively: Foreign Currency Translation; $2.5 billion, $(1.1) billion and $797 million; Employee Benefit Plans: $214 million, $86 million and $(289) million, Derivatives & Hedges: $388 million, $(365) million and $(39) million.

Amounts presented for 2023 have not been recast to exclude discontinued operations

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.